Web15 giu 2024 · SAN JOSE, Calif., June 15, 2024 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery ... Web15 giu 2024 · Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer SAN JOSE, Calif., June 15, 2024 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. …
Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief ... - EPICOS
WebAfridi Hasan is on Facebook. Join Facebook to connect with Afridi Hasan and others you may know. Facebook gives people the power to share and makes the world more open … Web8 mar 2024 · “This study highlights the efficacy limitations of standard of care antibiotics and therefore the unmet medical needs in high-risk, vulnerable patient populations such as older adults and those infected with antibiotic-resistant MRSA; populations where AR-301 has the potential to fulfill an unmet need,” Hasan Jafri, M.D., Aridis’ chief medical officer, said in … snd_soc_component_init_regmap
Aridis Pharmaceuticals Inc. (NASDAQ: ARDS)
Web10 dic 2024 · Aridis' COVID-19 therapy is particularly exciting. AR-711 is an ... As Hasan Jafri, M.D., CMO, elaborated, “Our Phase II ... IIa is expected to be complete in 2024, Phase IIb in 2024, and Phase III in 2024, with licensure shortly afterward,” Jafri predicted. Reimbursement is expected at full pulmonary status for premium-branded ... Web15 giu 2024 · SAN JOSE, Calif., June 15, 2024 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it has appointed Dr. Hasan Jafri as Chief Medical Officer (CMO). Dr. Hasan Jafri, M.D. Chief Medical Officer Dr. Jafri comes to Aridis from AstraZeneca, where he served as Senior Medical Director, Clinical Research and Development, Microbial Sciences, Clinical Head of Antibacterial mAb Program. road tax renewal letter